JP2019517491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517491A5 JP2019517491A5 JP2018562564A JP2018562564A JP2019517491A5 JP 2019517491 A5 JP2019517491 A5 JP 2019517491A5 JP 2018562564 A JP2018562564 A JP 2018562564A JP 2018562564 A JP2018562564 A JP 2018562564A JP 2019517491 A5 JP2019517491 A5 JP 2019517491A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- linker
- halo
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344338P | 2016-06-01 | 2016-06-01 | |
| US62/344,338 | 2016-06-01 | ||
| PCT/US2017/035391 WO2017210395A1 (en) | 2016-06-01 | 2017-06-01 | Use of ezh2 inhibitors for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517491A JP2019517491A (ja) | 2019-06-24 |
| JP2019517491A5 true JP2019517491A5 (enExample) | 2020-07-09 |
| JP7121660B2 JP7121660B2 (ja) | 2022-08-18 |
Family
ID=60477941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562564A Expired - Fee Related JP7121660B2 (ja) | 2016-06-01 | 2017-06-01 | 癌を処置するためのｅｚｈ２阻害剤の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11786533B2 (enExample) |
| EP (1) | EP3464643A4 (enExample) |
| JP (1) | JP7121660B2 (enExample) |
| AU (1) | AU2017273726B2 (enExample) |
| CA (1) | CA3025933A1 (enExample) |
| WO (1) | WO2017210395A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| WO2018102687A2 (en) * | 2016-12-02 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) * | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| JP7399079B2 (ja) * | 2017-09-05 | 2023-12-15 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| US20210260051A1 (en) * | 2018-06-14 | 2021-08-26 | Board Of Regents, The University Of Texas System | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| CN114269748A (zh) | 2019-06-05 | 2022-04-01 | 米拉蒂医疗股份有限公司 | 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物 |
| WO2021063331A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 |
| US12502434B2 (en) | 2019-10-31 | 2025-12-23 | Daegu-Gyeongbuk Medical Innovation Foundation | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient |
| CN111303133A (zh) * | 2020-03-25 | 2020-06-19 | 清华大学 | 降解ezh2蛋白的小分子化合物 |
| EP4267136A4 (en) * | 2020-12-23 | 2025-02-05 | Cascade Prodrug Inc. | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor |
| CN119136808A (zh) * | 2022-12-30 | 2024-12-13 | 清华大学 | 药物组合物及其应用 |
| WO2024238381A1 (en) * | 2023-05-12 | 2024-11-21 | Taipei Medical University | Dual ezh2-hsp90 inhibitors |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2482903A (en) * | 2010-08-19 | 2012-02-22 | Software Imaging Technology Ltd | A print engine |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3363B1 (ar) * | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA3177515A1 (en) | 2012-03-12 | 2013-09-19 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| ES2617379T3 (es) | 2012-04-13 | 2017-06-16 | Epizyme, Inc. | Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana |
| EP2836216B1 (en) | 2012-04-13 | 2022-06-08 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9445426B2 (en) * | 2012-08-06 | 2016-09-13 | Broadcom Corporation | Apparatuses, methods and computer program products related to improvements in autonomous denial prohibition mechanisms |
| US20140062720A1 (en) * | 2012-09-06 | 2014-03-06 | John Murray Spruth | Remote Pipeline Corrosion Protection and Valve Monitoring Apparatus |
| BR112015008480A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | compostos de benzeno substituído |
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| US20150283142A1 (en) * | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| EP2934531A4 (en) * | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| US20160031907A1 (en) | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
| WO2014165422A1 (en) | 2013-04-02 | 2014-10-09 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| PE20161273A1 (es) | 2013-10-16 | 2016-12-18 | Epizyme Inc | Forma salina de hidrocloruro para la inhibicion de ezh2 |
| WO2015058125A1 (en) | 2013-10-18 | 2015-04-23 | Epizyme, Inc. | Method of treating cancer |
| MX373187B (es) | 2013-12-06 | 2020-04-13 | Epizyme Inc | Terapia de combinación para tratar cáncer. |
| US20150320754A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EA038337B1 (ru) | 2014-06-17 | 2021-08-11 | Эпизим, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| EP3160940A4 (en) | 2014-06-25 | 2018-05-02 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| CN106794177A (zh) * | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| KR102964530B1 (ko) | 2014-11-17 | 2026-05-13 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| MX375970B (es) | 2014-12-23 | 2025-03-06 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos. |
| MX391720B (es) | 2015-04-20 | 2025-03-21 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| EA201890009A1 (ru) | 2015-06-10 | 2018-07-31 | Эпизайм, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| CA2994394A1 (en) * | 2015-08-03 | 2017-02-09 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibitors and modulation of regulatory t-cell function |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| US20180296563A1 (en) | 2015-09-25 | 2018-10-18 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor |
| WO2017062495A2 (en) | 2015-10-06 | 2017-04-13 | Epizyme, Inc. | Method of treating medulloblastoma with an ezh2 inhibitor |
| WO2017079757A1 (en) | 2015-11-06 | 2017-05-11 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
| EP3386513A2 (en) | 2015-12-07 | 2018-10-17 | Epizyme Inc | Inhibitors of ezh2 and methods of use thereof |
| US11951108B2 (en) | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| US20190038633A1 (en) | 2016-02-08 | 2019-02-07 | Epizyme, Inc. | Methods of treating cancer |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| WO2018102687A2 (en) | 2016-12-02 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN110366413A (zh) | 2017-02-02 | 2019-10-22 | Epizyme股份有限公司 | 癌症治疗形式 |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
-
2017
- 2017-06-01 US US16/306,182 patent/US11786533B2/en active Active
- 2017-06-01 WO PCT/US2017/035391 patent/WO2017210395A1/en not_active Ceased
- 2017-06-01 CA CA3025933A patent/CA3025933A1/en active Pending
- 2017-06-01 EP EP17807460.5A patent/EP3464643A4/en not_active Withdrawn
- 2017-06-01 AU AU2017273726A patent/AU2017273726B2/en not_active Expired - Fee Related
- 2017-06-01 JP JP2018562564A patent/JP7121660B2/ja not_active Expired - Fee Related
-
2023
- 2023-09-06 US US18/462,229 patent/US20240139203A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10092567B2 (en) | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | |
| JP2023012508A (ja) | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 | |
| JP2021502403A5 (enExample) | ||
| CN111801334A (zh) | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 | |
| TW201825099A (zh) | 使用包含parp抑制劑的組合產品治療癌症 | |
| JP2018527383A5 (enExample) | ||
| CN111065411A (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2017514795A5 (enExample) | ||
| JP2018516969A5 (enExample) | ||
| JP2019517512A5 (enExample) | ||
| HRP20201821T1 (hr) | Inhibitori arginaze i njihove terapeutske primjene | |
| JP2015534579A5 (enExample) | ||
| US20210228553A1 (en) | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer | |
| CA2868000C (en) | Pharmaceutical combination comprising a mek inhibitor compound and an a nti-igfir antibody for treating cancer | |
| JP2015500209A5 (enExample) | ||
| JP2015536986A5 (enExample) | ||
| RU2018146812A (ru) | Фармацевтические комбинации | |
| CN112512580B (zh) | Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP6824906B2 (ja) | 併用療法 | |
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP2019525948A5 (enExample) | ||
| JP2019048822A (ja) | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用 | |
| TWI806236B (zh) | 用於治療肺癌之包含ｋｒａｓｇ１２ｃ抑制劑及ｐｄ-ｌ１結合拮抗劑的方法及組成物 | |
| US20220062294A1 (en) | Pharmaceutical compositions of tetracyclic quinolone analogs and their salts | |
| CN112384219A (zh) | Sumo-激活酶抑制剂和抗cd20抗体的施用 |